Casopitant: A novel NK1-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 375-384

  Ruhlmann, Christina ^a   Herrstedt, Jørn ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Casopitant; Chemotherapy; Emesis; GW679769; NK1 receptor antagonist

Indexed keywords

2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CARBON 14; CARBOPLATIN; CASOPITANT; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOLASETRON MESILATE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GRANISETRON; KETOCONAZOLE; METOCLOPRAMIDE; NAVELBINE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; ORAL CONTRACEPTIVE AGENT; OXALIPLATIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SUBSTANCE P; TAXANE DERIVATIVE; WARFARIN;

ADD ON THERAPY; ALOPECIA; ANEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PRACTICE; CONSTIPATION; DIGESTIVE SYSTEM CANCER; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; FATIGUE; FUNCTIONAL LIVING INDEX EMESIS; HEADACHE; HICCUP; HIGH RISK PATIENT; HUMAN; ISOTOPE LABELING; LEUKOPENIA; NAUSEA; NAUSEA AND VOMITING; NEUROPHARMACOLOGY; NEUTROPENIA; NONHUMAN; POSTOPERATIVE NAUSEA AND VOMITING; PRACTICE GUIDELINE; QUALITY OF LIFE INDEX; QUESTIONNAIRE; RECEPTOR BLOCKING; REPEATED DRUG DOSE; REVIEW; SEROTONINERGIC SYSTEM; SINGLE DRUG DOSE; TREATMENT OUTCOME;

EID: 70349272658     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Coates A, Abraham S, Kaye SB, et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19:203-208.
2. Griffin AM, Butow PN, Coates AS, et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996;7:189-195.
3. Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981;305:905-909.
4. Italian Group for Antiemetic Research. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet. 1992;340:96-99.
5. Marty M, Pouillart P, Scholl S, et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med. 1990;322:816-821.
6. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the aprepitant protocol 052 study group. J Clin Oncol. 2003;21:4112-4119.
7. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the Neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer. 2003;97:3090-3098.
8. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822-2830.
9. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17:1000-1006.
10. Peroutka SJ, Snyder SH. Antiemetics: Neurotransmitter receptor binding predicts therapeutic actions. Lancet. 1982;1(8273):658-659.
11. Borison HL, McCarthy LE. Neuropharmacology of chemotherapyinduced emesis. Drugs. 1983;25:(Suppl 1):8-17.
12. Andrews PLR, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci. 1988; 9(9):334-341.
13. Miner WD, Sanger GJ, Turner DH. Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis. Br J Cancer. 1987;56(2):159-162.
14. Von Euler US, Gaddum JH. An unindentified depressor substance in certain tissue extracts. J Physiol (Lond). 1931;74-87.
15. Chang M, Leeman SE. Isolation of sialogogic peptide from bovine hypothalamic tissue and its characteristic as substance P. J Biol Chem. 1970;245:18:4784-4790.
16. Maggi CA. The mammalian tackykinin receptors. Gen Pharmac. 1995;26:5:911-944.
17. Carpenter DO, Briggs DB, Strominger N. Peptide-induced emesis in dogs. Behav Brain Res. 1984;11(3):277-281.
18. Andrews PLR, Bhandari P. Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology. 1993;32:8:799-806.
19. 1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in the ferret. Neuropharmacology. 1996;35: 1121-1129.
20. Diemunsch P, Grélot L. Potential of substance P antagonists as antiemetics. Drugs. 2000;60:533-546.
21. 1) receptor. Science. 1991;251:435-437.
22. 1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol. 1993;249:R3-R4.
23. 1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol. 1993;250:R5-R6.
24. 1 receptor antagonist GR203040. Br J Pharmacol. 1995;116:3158-3163.
25. 3 receptors. Eur J Pharmacol. 2001;428:215-220.
26. Minthorn E, Mencken T, King AG, et al. Pharmacokinetics and brain penetration of casopitant, a potent and selective neurokinin-1 receptor antagonist, in the ferret. Drug Metab Dispos. 2008;36:1846-1852.
27. 1 receptor antagonist, GW679769, in cisplatin-induced acute and delayed emesis in the ferret. Support Care Cancer. 2005;13:401-483:Abs 04-030.
28. 1 receptor antagonist GW679769 and aprepitant in the ferret. Support Care Cancer. 2005;13:401-483:Abs 04-031.
29. 1 receptor antagonist, casopitant mesylate, in cisplatin-induced delayed emesis in the ferret. J Clin Oncol 2006;24(Suppl 18):Abs 18601.
30. 1 receptor antagonist, results in augmented anti-emetic activity in the ferret. J Clin Oncol. 2006;24(Suppl 18): Abs 18608.
31. 1 receptor antagonist, in patients undergoing treatment with moderately and highlyemetogenic chemotherapy. Clin Pharmacol Ther. 2007;81(Suppl 1): Abs PIII30.
32. Johnson BM, Hoke JF, Bandekar R, Blackburn LM, Levin J, Russo MW. Casopitant for the prevention of post-operative nausea and vomiting (PONV): population pharmacokinetics and pharmacodynamics (PK/PD). Clin Pharmacol Ther. 2007;81(Suppl 1):Abs PIII29.
33. Adams L, Johnson B, Ke Zhang, Lin Yue, Kirby L, Stoltz R. Minimal impact of casopitant, novel neurokinin-1 receptor antagonist, on the pharmacokinetics of dolasetron and granisetron. Support Care Cancer. 2009;DOI 10.1007/s00520-008-0572-4.
34. 1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer. 2009;DOI 10.1007/s00520-008-0571-5.
35. 1) receptor antagonist for prevention of chemotherapy induced nausea and vomiting (CINV), on the pharmacokinetics (PK) and pharmacodynamics (PD) of steady-state warfarin. J Clin Oncol. 2008;26:(Suppl 15):Abs 20587.
36. Macapinlac M, Biggs DD, Guarino M, Johnson BM, Lebowitz PF, Su S-F. Interim results of an open-label, repeat dose, randomized, crossover study to investigate safety and potential pharmacokinetic interactions between the oral neurokinin-1 receptor antagonist casopitant mesylate and intravenous cyclophosphamide in cancer patients. Proceedings of the 29th Annual San Antonio Breast Cancer Symposium. 2006; Abs 6088.
37. Adams L, Johnson B, Bauman J, et al. Effect of oral (po) casopitant, a novel neurokinin-1 receptor antagonist, on the pharmacokinetics (PK) and safety profile of intravenous (iv) docetaxel. Proceedings of the 20th EORTC-NCI-AACR Symposium: Molecular Targets and Cancer Therapeutics. 2008;Abs 396.
38. 1 receptor antagonist. Poster presented at the American Society for Health-System Pharmacists meeting;2008.
39. Johnson B, Zhang K, Fang L, et al. Use of modeling and simulation in the QTc assessment of casopitant. Philadelphia, PA: Poster presented at American College of Clinical Pharmacology 36th Annual Meeting; September 14-16, 2008.
40. 1 RA) casopitant mesylate for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol. 2006;24:(Suppl 18):Abs 8512.
41. 1) receptor antagonist, casopitant, in patients with GI cancers receiving oxaliplatin-based chemotherapy (OX): Subgroup analysis from a randomized, double-blind, placebocontrolled phase II trial. Proceedings of the ASCO Gastrointestinal Cancers Symposium. 2008;Abs 359.
42. 1) receptor antagonist, casopitant, in women with breast cancer (BC) receiving moderately emetogenic chemotherapy (MEC) - subgroup analysis from a randomized, double-blind, placebocontrolled phase II trial. Proceedings of the 6th European Breast Cancer Conference (EBCC6). 2008;Abs 492.
43. 1 RA), casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapyinduced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy. J Clin Oncol. 2006;24(Suppl 18): Abs 8513.
44. 1) receptor antagonist, casopitant: Single oral and 3-day oral dosing regimens for chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol. 2008;26:(Suppl 15); Abs 9540.
45. 1) receptor antagonist, casopitant: 3-day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol. 2008;26(Suppl 15):2008; Abs 20512.
46. 1) receptor antagonist, casopitant: in the prevention of chemotherapy-induced nausea and vomiting (CINV) In patients receiving highly emetogenic chemotherapy (HEC). Support Care Cancer. 2008;16:619-756:Abs 01-008.
47. 1) receptor antagonist, casopitant: 3-day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving highly emetogenic chemotherapy (HEC). J Clin Oncol. 2008;26:(Suppl 15):Abs 20585.
48. Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res. 1992;1:331-340.
49. 1) receptor antagonist, improves the quality of life of patients receiving highly emetogenic chemotherapy (HEC). Support Care Cancer. 2008; 16:619-756:Abs 01-009.
50. The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2006;17:20-28.
51. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006. J Clin Oncol. 2006;24:2932-2947.
52. NCCN Clinical Practice Guidelines in Oncology. Antiemesis v.3. 2008. Accessed on March 1, 2009. Available from: http://www.nccn.org/.
53. GlaxoSmithKline. Casopitant and zofran to prevent post operative nausea and vomiting in women. No results available. October 15, 2008. Accessed on March 1, 2009. Available from: http://ClinicalTrials.gov/show/NCT00334152.